Genes Highlight Who’ll Benefit From Multiple Myeloma Therapy
WEDNESDAY, Dec. 4, 2024 (HealthDay News) — Genetic tests can show which patients with the blood cancer multiple myeloma should respond to targeted therapy, a new study finds. A special six-gene pattern can help predict who are more likely to respond well to Venclexta (venetoclax), a pill that promotes naturalContinue Reading